Shares of 10x Genomics, Inc. (TXG) surged 11.54% in after-hours trading on Thursday, following the release of the company's third-quarter 2025 financial results that exceeded analyst expectations. The biotech firm, known for its innovative genomics and single-cell analysis technologies, reported better-than-anticipated earnings and revenue figures, sparking investor enthusiasm.

For the third quarter, 10x Genomics posted earnings per share (EPS) of $(0.22), beating the estimated $(0.29). Revenue came in at $149.002 million, surpassing the forecast of $142.490 million. The company's gross margin stood at a healthy 67%, indicating strong profitability in its core operations. Despite reporting a net loss of $27.5 million for the quarter, the narrower-than-expected loss seemed to bolster investor confidence.

Adding to the positive sentiment, 10x Genomics provided an optimistic outlook for the fourth quarter, projecting revenue between $154 million and $158 million. This forward-looking guidance suggests continued growth and may have contributed to the stock's significant after-hours rally. Investors appear to be betting on the company's potential for future expansion in the rapidly evolving genomics market.